BRL Medicine key facts
- Developer of gene editing and cell engineering platforms intended for genetic and immune-related disorders.
- It has raised $55.6M; the latest was Secondary Transaction - Private in Oct 2025.
- Notable investors include Oriental Fortune Capital, Zizhu Xiaomiao PE, Gopher Asset Management, Ancheng Capital, China Resources Capital Management — 14 tracked in total.
- Status: Privately Held (backing).
Who backs BRL Medicine
14+Membership and data by Private Market View
- ·The complete investor list: 14 names
- ·Watch BRL Medicine: the Monday email on marks, rounds and moves
BRL Medicine funding rounds
No funding rounds for BRL Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BRL Medicine investors
14 investors are on record for BRL Medicine, including Oriental Fortune Capital, Zizhu Xiaomiao PE, Gopher Asset Management and Ancheng Capital.
About BRL Medicine
Developer of gene editing and cell engineering platforms intended for genetic and immune-related disorders. The company offers an integrated technology ecosystem that includes hematopoietic stem cell modification, universal immune cell engineering, non-viral CAR-T integration, enhanced T-cell development, and in vivo gene editing capabilities, enabling research institutions and clinical developers to create precise, adaptable treatments that improve therapeutic outcomes and support next-generation regenerative medicine.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Employees
- 153
- Website
- brlmed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
BRL Medicine doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.